Friday, July 10, 2026

Drug profile · INN

cipaglucosidase alfa

cipaglucosidase alfa (POMBILITI) is a glycogen hydrolytic enzyme.

EMA: approved Alimentary tract and metabolism (A16) A16AB
Patents linked 0
Pipeline programs 2
News articles 1
Drug details — cipaglucosidase alfa

Quick answer

cipaglucosidase alfa (POMBILITI) is a glycogen hydrolytic enzyme.

Key facts

INN cipaglucosidase alfa
Brand POMBILITI
Mechanism Glycogen hydrolytic enzyme
Target Glycogen
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16AB

Mechanism of action

Glycogen hydrolytic enzyme

Primary target: Glycogen

Approval history

Authority Status Date
EMA approved

Recent coverage

Pipeline programs

  1. Cipaglucosidase Alfa Phase 3 · Pacalis Therapeutics Pty · Pompe Disease (Late-onset)
  2. Myozyme powder for concentrate for solution f... for Pompe disease Approved · Disc Medicine · Pompe disease

Related & competitor drugs

  1. agalsidase alfa Alimentary tract and metabolism (A16)
  2. alogliptin Alimentary tract and metabolism (A10)
  3. alogliptin benzoate Alimentary tract and metabolism (A10)
  4. aprepitant Alimentary tract and metabolism (A04)
  5. budesonide Alimentary tract and metabolism (A07)
  6. canagliflozin Alimentary tract and metabolism (A10)

Frequently asked questions

What is cipaglucosidase alfa?

cipaglucosidase alfa (POMBILITI) is a glycogen hydrolytic enzyme.

What is the brand name for cipaglucosidase alfa?

POMBILITI is a marketed brand name for cipaglucosidase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.